logo

UNITED KINGDOM (UK) DIABETES CARE DEVICES MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

The United Kingdom diabetes care devices market is segmented into Management Devices (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors) and Monitoring Devices (Self-monitoring Blood Glucose and Continuous Glucose Monitoring). The report offers the value (in USD million) for the above segments.

Home Industry Reports Healthcare UNITED KINGDOM (UK) DIABETES CARE DEVICES MARKET - GROWTH, TRENDS, COVID-19 IMPA ...

Market Snapshot

UK Diabetes Care Devices Market Overview
Study Period: 2016-2027
Base Year: 2021
CAGR: >5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The United Kingdom diabetes care devices market is expected to reach USD 1.5 billion by 2027, registering a CAGR of more than 5% during 2022- 2027.

The COVID-19 pandemic had a substantial impact on the United Kingdom’s diabetes care devices. According to The British Diabetic Association, “The pandemic has had and continues to have, a huge impact on our society. But research and data have shown that people with diabetes have been disproportionately affected by COVID-19, particularly in terms of poorer outcomes when contracting the virus. That’s why preventing or delaying cases of type 2 diabetes is more important than ever before.”

The pandemic also highlighted opportunities for continuing and expanding innovations in the delivery of diabetes care, through virtual consultations between healthcare providers and people with diabetes, and the use of diabetes technology. Crisis management has created unprecedented interest in remote care from both patients and providers and removed many long-standing regulatory barriers. Thus, the COVID-19 outbreak increased the diabetes care device market's growth.

The rate of newly diagnosed cases of Type 1 and Type 2 diabetes is seen to increase, mainly due to obesity, unhealthy diet, and physical inactivity. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of the increasing usage of diabetic care products. According to The British Diabetic Association, Diabetes prevalence 2021 data shows an increase in the number of people living with a diabetes diagnosis in the UK: an increase of more than 150,000 from 2020. It is estimated that more than 13.6 million people are at increased risk of type 2 diabetes in the UK. At this rate, the number of people with diabetes, including the undiagnosed population, is expected to rise to 5.5 million by 2030.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Scope of the Report

The United Kingdom diabetes care devices market is segmented into Management Devices (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors) and Monitoring Devices (Self-monitoring Blood Glucose and Continuous Glucose Monitoring). The report offers the value (in USD million) for the above segments.

By Product
By Monitoring Devices, Value and Volume (2016-2027)
Self-monitoring Blood Glucose Devices
Glucometer Devices
Blood Glucose Test Strips
Lancets
Continuous Glucose Monitoring
Sensors
Durables
By Management Devices, Value and Volume (2016-2027)
Insulin Pump
Insulin Pump Device
Insulin Pump Reservoir
Infusion Set
Insulin Syringes
Cartridges in Reusable Pens
Insulin Disposable Pens
Jet Injectors

Report scope can be customized per your requirements. Click here.

Key Market Trends

Continuous Glucose Monitoring Segment is Expected to Witness a Healthy Growth Rate Over the Forecast Period

Continuous Glucose Monitoring Segment recorded more than USD 180 million in revenue in 2021, which is expected to further increase with a CAGR of more than 13% during the forecast period.

Continuous glucose monitoring sensors use glucose oxidase to detect blood sugar levels. Glucose oxidase converts glucose to hydrogen peroxidase, which reacts with the platinum inside the sensor, producing an electrical signal to be communicated to the transmitter. Sensors are the most important part of continuous glucose monitoring devices. Technological advancements to improve the accuracy of the sensors are expected to drive segment growth during the forecast period.

The COVID-19 pandemic emphasizes the need for good glycemic control in patients with diabetes, in large part because most observational studies have reported that poorly controlled diabetes is associated with a higher risk for hospitalization and death from a viral illness. The frequency of monitoring glucose levels depends on the type of diabetes, which varies from patient to patient. Type-1 diabetic patients need to check their blood glucose levels at regular intervals, in order to monitor their blood glucose levels and adjust the insulin dosing accordingly. The current CGM devices show a detailed representation of blood glucose patterns and tendencies compared to a routine check of glucose levels at set intervals.Furthermore, the current continuous glucose monitoring devices can either retrospectively display the trends in the levels of blood glucose by downloading the data or give a real-time picture of glucose levels through receiver displays. Continuous glucose monitoring devices are becoming cheaper with the advent of new technologies, like cell phone integration, is likely to drive the segment growth during the forecast period.

CGM Revenue

Insulin cartridges in reusable pens Occupied the Highest Share in the Management Devices Segment in 2021

Insulin cartridges in reusable pens occupied the highest market share of about 40% in the management devices segment in 2021.

Insulin cartridges in reusable pens currently have the highest demand among all insulin delivery devices in the United Kingdom market. Insulin cartridges in reusable pens are an upgraded version of insulin vials. Most types of insulins are manufactured in the form of cartridges, making them easily accessible. These devices have all the functional benefits of reusable pens and are cost-effective, as these cartridges are less expensive compared to disposable insulin pens in the long run. Due to the increasing demand for insulin cartridges, most insulin device manufacturing companies have produced reusable insulin pens that are compatible with various insulin manufacturers' cartridges. These insulin cartridges are considered more consumer-friendly, as they are smaller and less noticeable than the classic vial-and-syringe. These devices are also more portable for consumers on the go. Cartridges that are open do not need to be refrigerated, making storage very easy for consumers. Thus, cartridges are the most cost-effective way to use insulin, as reusable pens are a one-time investment, unlike disposable pens.

The National Service Framework (NSF) program is improving services by setting national standards to drive up service quality and tackle variations in care. In 2019, The Association of British HealthTech Industries (ABHI) launched a diabetes section, enabling diabetes technology companies to work together in the first forum of its kind. The ABHI group is for any health technology company with an interest in diabetes care, from CGM and insulin pumps to apps. Such advantages have helped the rise in the adoption of these products in the United Kingdom market.

Insulin cartridges in reusable pens

Competitive Landscape

The United Kingdom diabetes care devices market is moderately fragmented, with few significant and generic players. There have been constant innovations driven by manufacturers to compete in the market. The major players, such as Abbott and Medtronic, have undergone many mergers, acquisitions, and partnerships to establish market dominance, while also adhering to organic growth strategies, which is evident from the R&D spending of these companies. The manufacturers of insulin delivery devices are spending a massive amount on the R&D of the devices.

Abbott, Roche, Johnson & Johnson, Dexcom, Medtronic, ARKRAY Inc., Ascensia Diabetes Care, AgaMatrix, Bionime Corporation, Novo Nordisk, Eli Lilly, Sanofi, Rossmax International Ltd

Recent Development

  • In April 2022, Abbott, CamDiab, and Ypsomed announced that they are partnering to develop and commercialize an integrated automated insulin delivery (AID) system. The initial focus of the partnership will be in European countries. The connected, smart wearable solution is designed to continuously monitor a person's glucose levels and automatically adjust and deliver the right amount of insulin at the right time, removing the guesswork of insulin dosing.
  • In November 2021, ARKRAY, creator of the world’s first HLPC HbA1c clinical analyzer launched its brand in the UK and Europe. Its innovative diabetes testing systems are being marketed and supported directly to customers, rather than through a distributor.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

    3. 4.3 Market Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. Market Segmentation

    1. 5.1 By Product

      1. 5.1.1 By Monitoring Devices, Value and Volume (2016-2027)

        1. 5.1.1.1 Self-monitoring Blood Glucose Devices

          1. 5.1.1.1.1 Glucometer Devices

          2. 5.1.1.1.2 Blood Glucose Test Strips

          3. 5.1.1.1.3 Lancets

        2. 5.1.1.2 Continuous Glucose Monitoring

          1. 5.1.1.2.1 Sensors

          2. 5.1.1.2.2 Durables

      2. 5.1.2 By Management Devices, Value and Volume (2016-2027)

        1. 5.1.2.1 Insulin Pump

          1. 5.1.2.1.1 Insulin Pump Device

          2. 5.1.2.1.2 Insulin Pump Reservoir

          3. 5.1.2.1.3 Infusion Set

        2. 5.1.2.2 Insulin Syringes

        3. 5.1.2.3 Cartridges in Reusable Pens

        4. 5.1.2.4 Insulin Disposable Pens

        5. 5.1.2.5 Jet Injectors

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetes Population (2016-2027)

    2. 6.2 Type-2 Diabetes Population (2016-2027)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company profiles

      1. 7.1.1 Abbott

      2. 7.1.2 Roche

      3. 7.1.3 Johnson & Johnson

      4. 7.1.4 Dexcom

      5. 7.1.5 Medtronic

      6. 7.1.6 ARKRAY Inc.

      7. 7.1.7 Ascensia Diabetes Care

      8. 7.1.8 AgaMatrix

      9. 7.1.9 Bionime Corporation

      10. 7.1.10 Novo Nordisk

      11. 7.1.11 Eli Lilly

      12. 7.1.12 Sanofi

      13. 7.1.13 Rossmax International Ltd

    2. 7.2 COMPANY SHARE ANALYSIS

      1. 7.2.1 Self-monitoring Blood Glucose Devices

        1. 7.2.1.1 Abbott Diabetes Care

        2. 7.2.1.2 Roche Holding AG

        3. 7.2.1.3 LifeScan

        4. 7.2.1.4 Others

      2. 7.2.2 Continuous Glucose Monitoring Devices

        1. 7.2.2.1 Dexcom Inc.

        2. 7.2.2.2 Medtronic PLC

        3. 7.2.2.3 Others

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The United Kingdom (UK) Diabetes Care Devices Market market is studied from 2016 - 2027.

The United Kingdom (UK) Diabetes Care Devices Market is growing at a CAGR of >5% over the next 5 years.

The United Kingdom (UK) Diabetes Care Devices Market is valued at 1 Billion USD in 2016.

The United Kingdom (UK) Diabetes Care Devices Market is valued at 1 Billion USD in 2027.

Abbott, Dexcom, Roche, Medtronic, Johnson & Johnson are the major companies operating in United Kingdom (UK) Diabetes Care Devices Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!